GNPX · XBRL financial data

Genprex financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GNPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	0	0	0	—
Research and development	7,303	8,608	11,510	17,617	10,535	9,429
General and administrative	10,636	10,970	12,295	13,444	10,632	6,087
Operating income (loss)	(17,962)	(19,601)	(23,831)	(31,076)	(21,174)	(15,516)
Interest income	19	5	90	215	64	—
Income tax expense (benefit)	—	—	0	0	3	0
Net income (loss)	(17,943)	(19,596)	(23,741)	(30,860)	(21,111)	(16,229)
Earnings per share, basic USD per share	—	(0.44)	(0.50)	(22.56)	(5.34)	(17.40)
Weighted average shares, basic thousands of shares	—	47,097	47,952	1,368	4,006	933

† Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (GNPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	27,320	38,629	20,954	6,738	1,602	7,831
Accounts receivable	0	0	35	0	—	—
Prepaid and other current assets	385	511	484	794	476	526
Total current assets	30,715	39,140	21,473	7,532	2,077	8,357
Property and equipment, net	39	49	23	8	0	0
Total assets	31,367	42,862	25,085	10,671	4,124	10,159
Total current liabilities	451	1,585	2,810	3,254	2,504	2,175
Total liabilities	—	1,585	—	—	2,504	2,197
Accumulated deficit	(58,422)	(78,018)	(102,828)	(133,688)	(154,799)	(171,028)
Total stockholders' equity	30,916	41,277	22,275	7,416	1,620	7,962
Total liabilities and equity	31,367	42,862	25,085	10,671	4,124	10,159
Common shares outstanding (cover page) thousands of shares	43,277	47,880	51,974	1,910	24,153	9,045

† Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (GNPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(17,943)	(19,596)	(23,741)	(30,860)	(21,111)	(16,229)
Stock-based compensation	4,246	4,278	4,732	5,409	3,303	—
Net cash from operating activities	(13,935)	(14,285)	(17,779)	(24,739)	(17,149)	(15,311)
Purchases of property and equipment	18	32	0	—	—	—
Net cash from investing activities	(2,337)	(84)	98	(71)	1	0
Proceeds from issuing common stock	41,590	25,678	6	10,593	12,012	21,540
Net cash from financing activities	41,590	25,678	6	10,593	12,012	21,540
Net change in cash	25,317	11,309	(17,675)	(14,216)	(5,136)	6,229

† Share count changed about 1/27 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 13x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Intensity Therapeutics	8,494	not reported	(2,500)*	3.3M	3.8 quarters	Q3 FY26 10-QSep 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 9:53 PM ET. The filing on SEC.gov is the record.